Lexeo Therapeutics, Inc.
LXEO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001907108
In the last 90 days, Lexeo Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 141 institutions reported holding it in 13F filings for Q2 2026, worth $410.9M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Lexeo Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +19 vs. Q2 2025
- Shares held
- 49.3M
- +7.08M (+16.8%) vs. Q2 2025
- Total value
- $327.5M
- +$157.6M (+92.8%) vs. Q2 2025
- New holders
- 26
- 50 more added
- Sold out
- 7
- 15 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LXEO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 141 | $410.9M |
| Q1 2026 | 139 | $458.7M |
| Q4 2025 | 146 | $759.2M |
| Q3 2025 | 109 | $327.5M |
| Q2 2025 | 90 | $169.9M |
| Q1 2025 | 88 | $100.0M |
| Q4 2024 | 90 | $194.2M |
| Q3 2024 | 69 | $268.8M |
| Q2 2024 | 60 | $426.3M |
| Q1 2024 | 54 | $361.5M |
| Q4 2023 | 31 | $217.1M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Lexeo Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 2,226,290 | $14.8M | 0.00% | +223,424+11.2% | Added |
| Millennium Management LLC | 2,313,642 | $15.4M | 0.01% | −522,650−18.4% | Reduced |
| Woodline Partners LP | 2,572,162 | $17.1M | 0.08% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 3,250,000 | $21.6M | 0.98% | +21,839+0.7% | Added |
| Citadel Advisors LLC | 3,719,043 | $24.7M | 0.02% | +111,076+3.1% | Added |
| Affinity Asset Advisors, LLC | 3,870,527 | $25.7M | 2.39% | +281,172+7.8% | Added |
| Balyasny Asset Management LLC | 3,913,788 | $26.0M | 0.05% | −95,349−2.4% | Reduced |
| Frazier Life Sciences Management, L.P. | 4,424,725 | $29.4M | 0.88% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 6,105,527 | $40.5M | 0.02% | +2,421,144+65.7% | Added |
| Omega Fund Management, LLC | 0 | $0 | 0.00% | −1,184,636−100.0% | Sold out |
| Ally Bridge Group (NY) LLC | 0 | $0 | 0.00% | −867,302−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −29,779−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −14,528−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −3,852−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −1−100.0% | Sold out |